Related Experiment Video

Updated: Jun 19, 2026

In vivo Bioluminescence Imaging of Tumor Hypoxia Dynamics of Breast Cancer Brain Metastasis in a Mouse Model
11:02

In vivo Bioluminescence Imaging of Tumor Hypoxia Dynamics of Breast Cancer Brain Metastasis in a Mouse Model

Published on: October 3, 2011

[Recent advances in the study of bioreductive drugs targeted tumor hypoxia]

Jing-Bao Liu1, Lei Fu, Yong-Zhou Hu

  • 1Department of Medicinal Chemistry, College of Pharmaceutical Sciences, Shanghai Jiaotong University, Shanghai 200240, China.

Yao Xue Xue Bao = Acta Pharmaceutica Sinica
|October 8, 2009
PubMed

Insights

Tumor hypoxia, a key factor in cancer progression and treatment resistance, is increasingly targeted by novel bioreductive drugs. This review highlights recent advances in these hypoxia-targeted therapies for improved cancer treatment outcomes.

Area of Science:

  • Oncology
  • Biochemistry
  • Pharmacology

Background:

  • Tumor hypoxia is integral to solid tumor development.
  • Hypoxia drives critical processes including drug resistance, recurrence, and metastasis.
  • Hypoxic tumor cells exhibit resistance to radiation and chemotherapy.

Purpose of the Study:

  • To review the latest advancements in bioreductive drugs targeting tumor hypoxia.
  • To highlight the therapeutic potential of hypoxia-targeted strategies.

Main Methods:

  • Literature review of recent research on bioreductive drugs.
  • Analysis of therapeutic progress in targeting tumor hypoxia.

Main Results:

  • Bioreductive drugs targeting tumor hypoxia have shown significant progress.
  • These agents represent a promising therapeutic avenue for various cancers.

Conclusions:

  • Targeting tumor hypoxia is a crucial strategy in cancer therapy.
  • Recent developments in bioreductive drugs offer new hope for overcoming treatment resistance.

More Related Videos

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells09:12

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...